December 29, 2025 8:12am

As I have written; “It’s been a good clue to be reducing “some” exposures, exiting some also-rans or questionable data delays”

December, Q4 and FY25 draws to an end in 3 sessions

Pre-open Signals: 3 Negative and 1 Positive Indications

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!

 

 

In the throes of the Santa Claus rally period, a historically strong time for the stock market. Since 1950, the S&P 500 has averaged a gain of more than 1% between the last five trading days of the year and the 1st 2 of the new year, according to the Stock Trader’s Almanac.

 

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is pumping the volume and share pricing? … https://www.regmedinvestors.com/articles/13812   

 

Monday (12/29): The pre-open Dow futures are DOWN -0.13% or (-63 points), the S&P futures are DOWN -0.28% or (-19 points) and the Nasdaq futures are DOWN -0.44% or (-113 points)

  • Stock futures trading are slipping Monday, 12/29,
  • European markets are mixed,
  • Asia Pacific markets traded mixed

Economic Data: None, light for the week

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Friday: The Dow closed DOWN -20.19 points or -0.04%, the S&P closed DOWN -2.11 points or -0.03% while the Nasdaq closed DOWN -20.2 points or -0.09%
  • Thursday was Christmas and markets were closed
  • Wednesday’s The Dow closed UP +22.26 points or +0.32%, the S&P closed UP +31.30 points or +0.46% while the Nasdaq closed UP +133.015 points or +0.57%
  • Tuesday: The Dow closed UP +79.73 points or +0.16%, the S&P closed UP +31.30 points or +0.46% while the Nasdaq closed UP +133.015 points or +0.57%
  • Monday: The Dow closed UP +227.79 points or +0.47%, the S&P closed UP +43.99 points or +0.64% while the Nasdaq closed UP +121.209 points or +0.52%
  • Last week: The S&P 500 was up +1.4%, the Dow +1% and the Nasdaq was also up +0.1%
  • The previous week: The S&P 500 was up +0.1%, the Dow slipped -0.7% and the Nasdaq was up +0.5%.
  • November ended: the S&P 500 and Dow were slightly higher, as the Nasdaq fell 2%,

 

Q4 – December, 1 holiday, 8 positive and 11 negative closes

  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Capricor Therapeutics (CAPR) closed up +$0.01 (having been down -$0.27) after Wednesday’s -$0.57) … with a positive +$0.42 or +1.41% pre-open

  • I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
  • Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
  • CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
  • It has begun; timing will be everything!

CRISPR Therapeutics (CRSP) dropped -$1.63 with a negative -$0.489 or -0.87% pre-open as

  • Although, Cathie Wood’s ARK Investment bought into CRSP and makes-up roughly 3.81% of assets; ARK loaded up on over 76,800 shares of CRISPR in just three trading days.

BioNTech (BNTX) closed down -$0.51 with a negative -$0.27 or -0.29% pre-open

Ionis Pharmaceuticals (IONS) closed down -$0.72 with a negative -$0.13 or -0.16% pre-open

  • Fundamentals have also been supportive, with innovation accelerating across high-growth areas, such as obesity, gene therapy, inflammation, and neuroscience. Regulatory activity remained healthy, with the FDA approving 43 novel therapies as of Dec. 22, 2025. Yahoo Finance>

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

  • Stocks are entering the final stretch of 2025 trading within striking distance their record highs,
  • With a downside end-of-month and year rotation and rebalance, In the last of December and 2025, it means investors have to be careful of slippage targets.

Streaking across sessions … however, it’s about ending 2025 without … considering what headwinds are about to be faced in the beginning months of 2026.

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

  • after a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

All 3 major indexes will enter the final 7 trading sessions of 2025 within 3% of their record highs.

  • In the week ahead, those investors still around during the holidays will turn their attention to the prospects of a “Santa Claus rally,” while a few pieces of economic data out on Tuesday will clean up some of the lagging data delayed as a result of the government shutdown.

 

4th week of December to include Christmas holiday

  • Friday closed negative with 11 positive, 28 negative and 1 flat
  • Thursday was a holiday
  • Wednesday closed positive with 31 positive, 5 negative and 4 flats - not published
  • Tuesday closed negative with 14 positive, 24 negative and 2 flats
  • Monday: Monday closed positive with 30 positive, 8 negative and 2 flats

3rd week of December:

  • 12/19 - Friday closed positive with 27 positive, 10 negative and 3 flats
  • 12/18 – Thursday closed positive with 22 positive, 16 negative and 2 flats
  • 12/17 – Wednesday closed negative with 12 positive, 26 negative and 2 flats
  • 12/16- Tuesday closed negative with 17 positive, 21 negative and 2 flats
  • 12/15 – Monday closed negative with 15 positive, 23 negative and 2 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.